Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting across several clinical pathways.

• Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of both acute and delayed episodes.
• Radiation‑induced nausea and vomiting: helps control nausea during and after radiotherapy.
• Postoperative nausea and vomiting: prevents nausea and vomiting following surgical procedures.

• Ondansetron blocks serotonin (5‑HT3) receptors located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents the initiation of the vomiting reflex triggered by chemotherapeutic agents, radiation, or surgical stimuli, thereby reducing nausea and vomiting.

Common Side Effects

• Headache: mild to moderate pain often reported after administration.
• Constipation: reduced bowel movements may occur.
• Dizziness: transient sensation of light‑headedness.
• Injection site reactions: redness, pain or swelling at the infusion site.

Serious or Rare Side Effects

• QT prolongation: may lead to cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, rash, or angioedema.
• Serotonin syndrome: risk when combined with other serotonergic drugs.
• Significant hypotension: sudden drop in blood pressure.
• Cardiac arrhythmias: irregular heart rhythms beyond QT issues.

Ondansetron Kabi should be used with consideration of patient‑specific factors and proper handling.

• Cardiac assessment: evaluate QT interval and electrolyte status before use.
• Concomitant QT‑prolonging agents: avoid or monitor closely.
• Pregnancy: use only if benefit outweighs potential risk.
• Breastfeeding: assess risk; drug may be excreted in milk.
• Pediatric use: dose and safety must be determined by a qualified clinician.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Ondansetron Kabi may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

• Other QT‑prolonging drugs: increase risk of life‑threatening arrhythmias.
• Apomorphine: may cause severe hypotension and syncope.
• Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Anesthetic agents (e.g., propofol, volatile anesthetics): monitor for additive sedation and cardiovascular effects.